The Name Game: Will Innovators’ Latest Battlefront Kill Biosimilars?
This article was originally published in RPM Report
Having lost the battle to prevent biosimilars reaching the market at all, innovators are now pushing for them to be stamped with unique international non-proprietary names. That could prove commercially fatal for copycat biologics.
You may also be interested in...
Sandoz has begun a global Phase III trial with its biosimilar version of Amgen's Enbrel (etanercept), targeting psoriasis rather than the more lucrative indication for rheumatoid arthritis, with the aim of winning quicker regulatory approval which can be built on as it gains insights testing the medicine.
Safeguarding America’s Pharmaceuticals Act passes on suspension calendar, but likely sets up fight with Senate in conference.
If approved in Europe this year, as expected, Celltrion/Hospira’s biosimilar infliximab will provide a compelling test of whether and how quickly budgetary pressures can override physician caution. It will also set the stage for the $70 billion worth of copycat antibodies in development.